Intel plans to start dispatching its 10nm processors by June this year
Category: #tech  By Mateen Dalal  Date: 2019-05-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Intel plans to start dispatching its 10nm processors by June this year

Future Intel Core i7 quad-core chips may have twice the graphics performance over its 8th-generation counterpart and up to three times the AI capabilities

Intel, the US semiconductor giant, has recently confirmed that its 10-nanometer processors are finally ready to ship in large volumes. After delaying for years, its mobile Ice Lake processors of 10nm will start shipping in June.

Intel’s Ice Lake processors will supposedly feature 2X graphics performance, 2.5X to 3.5X the AI performance, as well as 3X the wireless speeds compared to the Coffee Lake chips.

Apparently, Intel has not predicted when the first laptops based on the novel parts will be available but said that its future Core i7 quad-core chip will promote twice the graphics performance over its 8th-generation counterpart, up to three times the AI capabilities, and twice the video transcoding speed.

Sources familiar with the matter commented that one can expect numerous 10nm chips throughout 2019 and 2020, including server-side processors, a general-purpose GPU, and specialized parts like the AI-oriented Nervana. In addition, Intel revealed that its Ice Lake-SP data processors are already being shipped to its leading customers and its Cooper Lake processors of 14nm technology are in line for a 2020 delivery.

Reportedly, Intel has also announced its first product based on the denser and smaller 7nm technology, an Xe-based general-purpose GPU, arriving in 2021. The company is expecting around 20% boost in performance per watt, and the extreme ultraviolet lithography required to create it should be useful for several generations of small processes.

The company has also revealed that it will use its Embedded Multi-Die Interconnect Bridge (EMIB) and 3D Foveros technologies for the Xe-based Graphics Architecture. Intel’s new GP-GPU design would be powering the exascale Aurora supercomputer.

Sources further mentioned that, in many other ways, Intel could set a trend with this development. Intel can finally start providing sizeable generation-to-generation enhancements without having to stack on more cores, and users might find better reasons to upgrade their PC after years of ignoring incremental Intel revisions.

Source Credit: https://www.engadget.com/2019/05/08/intel-ships-volume-10nm-in-june/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Arranta Bio acquires Captozyme to accelerate microbiome development
Arranta Bio acquires Captozyme to accelerate microbiome development
By Mateen Dalal

Arranta has established a Center of Excellence for microbiome development   The acquisition will help quicken the delivery of LBPs for clients worldwide Arranta Bio, a leading Contract Development Manufacturing Organization, recently annou...

CytoDyn obtains IRB approval for leronlimab for patients with TNBC
CytoDyn obtains IRB approval for leronlimab for patients with TNBC
By Mateen Dalal

Reports confirm that CytoDyn Inc., a late-stage biotechnology company has announced that it has recently received approval from the Institutional Review Board for leronlimab, to be directed to triple-negative breast cancer (TNBC) patients under a com...

FDA declines approval of Lipocine’s oral drug Tlando for third time
FDA declines approval of Lipocine’s oral drug Tlando for third time
By Mateen Dalal

FDA declines approval of Lipocine’s oral drug Tlando for third time Reportedly, the oral drug Tlando was first declined  approval by FDA in the year 2016. The U.S. Food and Drug Administration (FDA)  declined the approval of oral dr...